PROCISE cLC Sequencing System 2 Cart w/PC

描述（由申请人提供）：申请购买Applied Biosystems公司的CLC测序系统。应用生物系统公司是唯一的蛋白质测序仪制造商。该测序仪是一种最先进的自动Edman蛋白质测序仪器。该仪器将取代15年前购买的过时的477A型测序仪。该测序仪的灵敏度大约是477A的100倍，477A是目前布里格姆妇女医院（BWH）生物聚合物实验室（BPL）核心蛋白质化学设施中唯一的蛋白质测序仪。自1984年以来，BPL为BWH、哈佛医学院及其附属教学医院以及美国和外国的其他机构的用户提供标准测序服务。此外，BPL是放射性序列分析的世界中心，这是由相对较少的实验室完成的。该技术使用预先放射性标记的蛋白质样品，通过在Edman化学的每个循环中检测到的放射性的周期性来鉴定特定氨基酸的位置。这种高灵敏度（阿托摩尔）方法允许序列测定的样品，否则不服从序列分析或质谱表征。十二个NIH资助的项目组成了我们的“主要用户群”。“预计测序样本的数量将使新仪器持续运行，以及对放射性测序能力的需求，使得购买NISISE仪器成为实现NIH资助用户组的目标所必需的。这些目标解决了与重要人类疾病相关的关键问题，包括阿尔茨海默病，帕金森病，多发性硬化症和骨质疏松症。除了提供研究这些疾病的手段外，CRISISE灵敏度的提高还将为研究低丰度蛋白质的研究人员开辟新的机会，这些研究人员由于过时的477仪器相对较低的灵敏度而无法将测序方法应用于他们的项目。 重要的是，正如在引入新的或改进的仪器后无数次发生的那样，我们完全期望，在理解和治疗人类疾病方面的不可预见的进展将通过使用ESPRISE仪器来实现。

DESCRIPTION (provided by applicant): Support is requested for the purchase of an Applied Biosystems PROCISE (r) cLC Sequencing System. Applied Biosystems is the only manufacturer of protein sequenators. The PROCISE is a state-of-the-art instrument for automated Edman protein sequencing. The instrument will replace an obsolete Model 477A sequenator that originally was purchased 15 years ago. The PROCISE is approximately 100-fold more sensitive than the 477A, which is currently the sole protein sequenator in a core protein chemistry facility, the Biopolymer Laboratory (BPL), at Brigham and Women's Hospital (BWH). Since 1984, the BPL has provided standard sequencing services to users at BWH, Harvard Medical School and its affiliated teaching hospitals, and other institutions in the US and in foreign countries. In addition, the BPL is a world center for radiosequence analysis, which is done by relatively few laboratories. This technique uses pre.facto radiolabeled protein samples to identify positions of specific amino acids through the periodicity of radioactivity detected in each cycle of the Edman chemistry. This highly sensitive (attomolar) method allows sequence determination of samples not otherwise amenable to sequence analysis or to mass spectrometric characterization. Twelve NIH-funded projects comprise our "major user group." The number of projected sequencing samples, which will keep the new instrument running continuously, and the need for radiosequencing capabilities, make purchase of the PROCISE instrument necessary to achieve the aims of the NIH grants funding the user group. These aims address key questions related to important human diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and osteoporosis. In addition to providing the means to study these diseases, the improved sensitivity of the PROCISE will open up new opportunities for researchers studying low abundance proteins and who were precluded from applying sequencing methods to their projects due to the relatively low sensitivity of the obsolete 477 instrument. Importantly, as has happened countless times following the introduction of new or improved instrumentation, we fully expect that unforeseen advances in the understanding and treatment of human disease will be enabled by the availability of the PROCISE instrument.